

# Michael A Weber

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6465083/publications.pdf>

Version: 2024-02-01

241  
papers

20,619  
citations

18436

62  
h-index

10127

140  
g-index

250  
all docs

250  
docs citations

250  
times ranked

13416  
citing authors

#	ARTICLE	IF	CITATIONS
1	2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action. <i>Journal of Human Hypertension</i> , 2023, 37, 428-437.	1.0	22
2	Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study. <i>Journal of Human Hypertension</i> , 2022, 36, 629-639.	1.0	14
3	Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2022, 21, 12.	2.7	11
4	Emerging Authors Program for Global Cardiovascular Disease Research-A collaboration of the U.S. Centers for Disease Control and Prevention, the Lancet Commission on Hypertension Group, Resolve to Save Lives, and the World Hypertension League. <i>Journal of Human Hypertension</i> , 2022, , .	1.0	2
5	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. <i>Circulation</i> , 2022, 145, 847-863.	1.6	28
6	Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL) Tj ETQq0 0 0 rgBT /Overlock 10 T	6.5	114
7	Hypertension research from Japan: advancing the field of renal denervation. <i>Hypertension Research</i> , 2022, 45, 188-192.	1.5	1
8	Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial. <i>Hypertension</i> , 2022, 79, 1506-1514.	1.3	10
9	Hypertension in stroke survivors and associations with national premature stroke mortality: data for 2A-5 million participants from multinational screening campaigns. <i>The Lancet Global Health</i> , 2022, 10, e1141-e1149.	2.9	10
10	Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial. <i>Clinical Research in Cardiology</i> , 2021, 110, 725-731.	1.5	17
11	Alcohol-Mediated Renal Sympathetic Neurolysis for the Treatment of Hypertension: The Peregrineâ„¢ Infusion Catheter. <i>Cardiovascular Revascularization Medicine</i> , 2021, 24, 77-86.	0.3	4
12	Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk. <i>Blood Pressure</i> , 2021, 30, 90-97.	0.7	4
13	Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension. <i>Blood Pressure</i> , 2021, 30, 82-89.	0.7	4
14	Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke. <i>Journal of Hypertension</i> , 2021, 39, 1602-1610.	0.3	5
15	Improved Understanding of Renal Nerve Anatomy. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 316-318.	1.1	3
16	Ambulatory Blood Pressure Monitoring to Predict Response to Renal Denervation. <i>Hypertension</i> , 2021, 77, 529-536.	1.3	15
17	Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. <i>Journal of Hypertension</i> , 2021, 39, 766-774.	0.3	9
18	Prioritised endpoints for device-based hypertension trials: the win ratio methodology. <i>EuroIntervention</i> , 2021, 16, e1496-e1502.	1.4	12

#	ARTICLE	IF	CITATIONS
19	Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. Journal of the American College of Cardiology, 2021, 77, 2909-2919.	1.2	63
20	Treating hypertension: who speaks for the patient?. Journal of Human Hypertension, 2021, 35, 1057-1058.	1.0	0
21	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN) Tj ETQq1 1 0.784314 rgBT /Overlo	6.3	197
22	Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension. Journal of Hypertension, 2021, 39, 1742-1767.	0.3	82
23	The World Hypertension League becomes a partner of the Journal of Human Hypertension. Journal of Human Hypertension, 2021, 35, 821-822.	1.0	0
24	Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by <scp>SCAI</scp> and <scp>NKF</scp>. Catheterization and Cardiovascular Interventions, 2021, 98, 416-426.	0.7	21
25	Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. Journal of the American College of Cardiology, 2021, 78, 1028-1038.	1.2	27
26	A re-examination of the SPYRAL HTN-OFF MED Pivotal trial with respect to the underlying model assumptions. Contemporary Clinical Trials Communications, 2021, 23, 100818.	0.5	3
27	Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications. American Heart Journal, 2021, 239, 90-99.	1.2	16
28	Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension. Circulation: Cardiovascular Interventions, 2021, 14, e010075.	1.4	8
29	Abstract P154: Win Ratio Methodology Demonstrates Consistency Of Benefit Across Different Blood Pressure Reduction Thresholds Following Renal Denervation In The Spyril Htn-on Med Pilot Study. Hypertension, 2021, 78, .	1.3	0
30	Impact of Renal Pelvic Denervation on Systemic Hemodynamics and Neurohumoral Changes in a Porcine Model. American Journal of Nephrology, 2021, 52, 429-434.	1.4	3
31	Building research capacity within cardiovascular disease prevention and management in low- and middle-income countries: A collaboration of the US Centers for Disease Control and Prevention, the Lancet Commission on Hypertension Group, Resolve to Save Lives, and the World Hypertension League. Journal of Clinical Hypertension, 2021, 23, 699-701.	1.0	5
32	Hypertension in Asia 2021: A major contribution to worldwide understanding and management of hypertension. Journal of Clinical Hypertension, 2021, 23, 403-405.	1.0	1
33	Measurement of Blood Pressure in Clinical Practice. American Journal of the Medical Sciences, 2021, 362, 533-534.	0.4	0
34	Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension. American Journal of Hypertension, 2021, 34, 531-539.	1.0	1
35	Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. European Heart Journal, 2020, 41, 231-238.	1.0	35
36	Systemic hemodynamic atherothrombotic syndrome (SHATS) â€“ Coupling vascular disease and blood pressure variability: Proposed concept from pulse of Asia. Progress in Cardiovascular Diseases, 2020, 63, 22-32.	1.6	54

#	ARTICLE	IF	CITATIONS
37	Methodological and Regulatory Considerations for Updated Guidance on the Pressor Effects of Drugs. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 1473-1476.	0.8	2
38	Global cardiovascular disease prevention and management: A collaboration of key organizations, groups, and investigators in low- and middle-income countries. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1293-1295.	1.0	4
39	12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2922-2933.	1.1	47
40	Blood Pressure—Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers. <i>Hypertension</i> , 2020, 75, 1584-1592.	1.3	11
41	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL) Tj ETQq1 1 0.784314 rgBT /Overle 1444-1451.	6.3	351
42	Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design. <i>Clinical Research in Cardiology</i> , 2020, 109, 289-302.	1.5	28
43	The REDUCE HTN: REINFORCE. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 461-470.	1.1	53
44	The new wave of Asia: A major step forward in confronting global hypertension. <i>Journal of Clinical Hypertension</i> , 2020, 22, 317-318.	1.0	1
45	Confounding Factors in Renal Denervation Trials. <i>Hypertension</i> , 2020, 76, 1410-1417.	1.3	33
46	Emergence of Home Blood Pressure-Guided Management of Hypertension Based on Global Evidence. <i>Hypertension</i> , 2019, 74, 229-236.	1.3	62
47	Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy. <i>Hypertension</i> , 2019, 74, 244-249.	1.3	17
48	Renal Denervation for Treating Hypertension. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1095-1105.	1.1	61
49	May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. <i>European Heart Journal</i> , 2019, 40, 2006-2017.	1.0	193
50	Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. <i>Circulation</i> , 2019, 139, 2542-2553.	1.6	97
51	Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. <i>European Heart Journal</i> , 2019, 40, 2032-2043.	1.0	47
52	The Accuracy in Measurement of Blood Pressure (AIM-BP) collaborative: Background and rationale. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1780-1783.	1.0	16
53	São Paulo call to action for the prevention and control of high blood pressure: 2020. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1744-1752.	1.0	53
54	Nocturnal blood pressure measured by home devices. <i>Journal of Hypertension</i> , 2019, 37, 905-916.	0.3	84

#	ARTICLE	IF	CITATIONS
55	Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. <i>European Heart Journal</i> , 2019, 40, 743-751.	1.0	70
56	Abstract 109: Changes in Plasma Renin Activity After Renal Denervation in the Spyral Htn-Off Med Trial. <i>Hypertension</i> , 2019, 74, .	1.3	1
57	Nocturnal hypertension in diabetes: Potential target of sodium/glucose cotransporter 2 (<sc>SGLT</sc>2) inhibition. <i>Journal of Clinical Hypertension</i> , 2018, 20, 424-428.	1.0	17
58	Comparative effectiveness of an angiotensin receptor blocker, olmesartan medoxomil, in older hypertensive patients. <i>Journal of Clinical Hypertension</i> , 2018, 20, 356-365.	1.0	8
59	Global Implications of Blood Pressure Thresholds and Targets. <i>Hypertension</i> , 2018, 71, 985-987.	1.3	11
60	Cardiovascular Safety of the $\beta$ -Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1084-1091.	1.0	15
61	A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. <i>Journal of Hypertension</i> , 2018, 36, 947-956.	0.3	4
62	Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	8
63	Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. <i>European Heart Journal</i> , 2018, 39, 2243-2251.	1.0	156
64	A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects. <i>Blood Pressure Monitoring</i> , 2018, 23, 153-163.	0.4	9
65	A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. <i>American Heart Journal</i> , 2018, 195, 115-129.	1.2	64
66	Twenty-Four-Hour Ambulatory Blood Pressure Reduction Patterns After Renal Denervation in the SPYRAL HTN-OFF MED Trial. <i>Circulation</i> , 2018, 138, 1602-1604.	1.6	36
67	A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2018, 19, 147032031879500.	1.0	2
68	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. <i>Lancet</i> , The, 2018, 391, 2346-2355.	6.3	597
69	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. <i>Lancet</i> , The, 2018, 391, 2335-2345.	6.3	526
70	May Measurement Month 2017: an analysis of blood pressure screening results worldwide. <i>The Lancet Global Health</i> , 2018, 6, e736-e743.	2.9	245
71	Blood pressure measurement in special populations and circumstances. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1122-1127.	1.0	20
72	Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140) mmHg in 10 trials. <i>European Heart Journal</i> , 2018, 39, 3105-3114.	1.0	92

#	ARTICLE	IF	CITATIONS
73	Abstract 070: Adherence to Antihypertensive Drugs: Insights from the SPYRAL HTN Trials and Implications for Hypertension Trial Design. <i>Hypertension</i> , 2018, 72, .	1.3	0
74	The technical report on sodium intake and cardiovascular disease in low- and middle-income countries by the joint working group of the World Heart Federation, the European Society of Hypertension and the European Public Health Association. <i>European Heart Journal</i> , 2017, 38, ehw549.	1.0	65
75	Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation. <i>Current Problems in Cardiology</i> , 2017, 42, 198-225.	1.1	17
76	Intensive treatment of hypertension to a SBP <math>\leq 120\text{ mmHg}</math> in patients aged 75 and over reduces mortality and cardiovascular events. <i>Evidence-Based Medicine</i> , 2017, 22, 30-30.	0.6	0
77	Evaluation of the angiotensin <math>II</math> receptor blocker azilsartan medoxomil in African-American patients with hypertension. <i>Journal of Clinical Hypertension</i> , 2017, 19, 695-701.	1.0	6
78	Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. <i>Lancet, The</i> , 2017, 389, 2226-2237.	6.3	263
79	Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status. <i>Journal of Clinical Hypertension</i> , 2017, 19, 1309-1318.	1.0	4
80	Blood pressure variability and cardiovascular prognosis: implications for clinical practice. <i>European Heart Journal</i> , 2017, 38, 2823-2826.	1.0	16
81	Expertise: No Longer a Sine Qua Non for Guideline Authors?. <i>Hypertension</i> , 2017, 70, 235-237.	1.3	4
82	Expertise. <i>Journal of Hypertension</i> , 2017, 35, 1564-1566.	0.3	12
83	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. <i>Lancet, The</i> , 2017, 390, 2160-2170.	6.3	597
84	High Blood Pressure 2016: Why Prevention and Control Are Urgent and Important. The World Hypertension League, International Society of Hypertension, World Stroke Organization, International Diabetes Foundation, International Council of Cardiovascular Prevention and Rehabilitation, International Society of Nephrology. <i>Journal of Clinical Hypertension</i> , 2016, 18, 714-717.	1.0	32
85	Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. <i>Journal of Clinical Hypertension</i> , 2016, 18, 299-307.	1.0	26
86	Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. <i>European Heart Journal</i> , 2016, 38, ehw325.	1.0	104
87	2016 Dietary Salt Fact Sheet and Call to Action: The World Hypertension League, International Society of Hypertension, and the International Council of Cardiovascular Prevention and Rehabilitation. <i>Journal of Clinical Hypertension</i> , 2016, 18, 1082-1085.	1.0	19
88	Contributions to Hypertension Public Policy and Clinical Practice: A Review of Recent Reports. <i>Journal of Clinical Hypertension</i> , 2016, 18, 1063-1070.	1.0	7
89	Is It Time to Reappraise Blood Pressure Thresholds and Targets?. <i>Hypertension</i> , 2016, 68, 266-268.	1.3	16
90	Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. <i>Blood Pressure</i> , 2016, 25, 93-103.	0.7	90

#	ARTICLE	IF	CITATIONS
91	Ambulatory Blood Pressure Monitoring: New Directions and Uncertainties Arise From the U.S. Preventive Services Task Force Recommendation on the Diagnosis of Hypertension. <i>Journal of Clinical Hypertension</i> , 2016, 18, 172-174.	1.0	7
92	Cardiovascular benefits of lowering blood pressure. <i>Nature Reviews Nephrology</i> , 2016, 12, 202-204.	4.1	18
93	Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 211-220.	5.5	185
94	Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. <i>European Heart Journal</i> , 2016, 37, 955-964.	1.0	95
95	No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. <i>Blood Pressure</i> , 2016, 25, 83-92.	0.7	59
96	The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. <i>American Heart Journal</i> , 2016, 171, 82-91.	1.2	132
97	Renal Denervation for the Treatment of Hypertension: Making a New Start, Getting It Right. <i>Clinical Cardiology</i> , 2015, 38, 447-454.	0.7	9
98	A Tribute to Dr John H. Laragh. <i>Journal of Clinical Hypertension</i> , 2015, 17, 495-498.	1.0	2
99	Remembering Dr Marvin Moser. <i>Journal of Clinical Hypertension</i> , 2015, 17, 1-4.	1.0	1
100	Renal denervation for the treatment of hypertension: Making a new start, getting it right. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 855-863.	0.7	3
101	Renal Denervation for the Treatment of Hypertension: Making a New Start, Getting It Right. <i>Journal of Clinical Hypertension</i> , 2015, 17, 743-750.	1.0	16
102	Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 845-854.	2.3	15
103	Interpreting Blood Pressure in Young Adults. <i>Journal of the American College of Cardiology</i> , 2015, 65, 336-338.	1.2	8
104	Amlodipine+Benazepril is Superior to Hydrochlorothiazide+Benazepril Irrespective of Baseline Pulse Pressure: Subanalysis of the ACCOMPLISH Trial. <i>Journal of Clinical Hypertension</i> , 2015, 17, 141-146.	1.0	4
105	Global Burden of Cardiovascular Disease and Stroke: Hypertension at the Core. <i>Canadian Journal of Cardiology</i> , 2015, 31, 569-571.	0.8	249
106	MY APPROACH to the patient with hard-to-control hypertension. <i>Trends in Cardiovascular Medicine</i> , 2015, 25, 755-756.	2.3	0
107	Optimum antihypertensive therapy: does adiposity matter?. <i>Lancet</i> , 2015, 385, 834-836.	6.3	1
108	Recently Published Hypertension Guidelines of the JNC 8 Panelists, the American Society of Hypertension/International Society of Hypertension and Other Major Organizations: Introduction to a Focus Issue of <i>The Journal of Clinical Hypertension</i> . <i>Journal of Clinical Hypertension</i> , 2014, 16, 241-245.	1.0	14

#	ARTICLE	IF	CITATIONS
109	<i>The Journal of Clinical Hypertension</i> Has Become the Official Journal of the World Hypertension League. <i>Journal of Clinical Hypertension</i> , 2014, 16, 319-319.	1.0	2
110	Clinical Practice Guidelines for the Management of Hypertension in the Community. <i>Journal of Clinical Hypertension</i> , 2014, 16, 14-26.	1.0	768
111	Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. <i>Blood Pressure Monitoring</i> , 2014, 19, 90-97.	0.4	10
112	Clinical Practice Guidelines for the Management of Hypertension in the Community. <i>Journal of Hypertension</i> , 2014, 32, 3-15.	0.3	498
113	John Laragh and the Renin Thesis: Creating a Paradigm. <i>American Journal of Hypertension</i> , 2014, 27, 1008-1009.	1.0	0
114	β <sub>2</sub> -Blockers and Cardiovascular Events in Patients With and Without Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 872-881.	0.9	84
115	Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. <i>Lancet, The</i> , 2014, 383, 1889-1898.	6.3	71
116	The Evolving Clinical Management of Hypertension. <i>Journal of Clinical Hypertension</i> , 2014, 16, 917-924.	1.0	8
117	Abstract 16107: Combined HbA1c and Systolic Blood Pressure Reduction With Dapagliflozin in Patients With Both Inadequately Controlled Type 2 Diabetes Mellitus and Hypertension. <i>Circulation</i> , 2014, 130, .	1.6	0
118	Abstract 13640: Dapagliflozin Lowers HbA1c, Systolic Blood Pressure and Serum Uric Acid in Patients With Type 2 Diabetes and Hypertension, Regardless of Class of Concomitant Antihypertensive Therapy. <i>Circulation</i> , 2014, 130, .	1.6	1
119	Systolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension. <i>American Journal of Medicine</i> , 2013, 126, 501-508.	0.6	56
120	Comparison of Benazepril Plus Amlodipine or Hydrochlorothiazide in High-Risk Patients With Hypertension and Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2013, 112, 255-259.	0.7	25
121	Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. <i>Lancet, The</i> , 2013, 381, 537-545.	6.3	132
122	Building the Case for Central Blood Pressure. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1788-1790.	1.2	3
123	Obesity, blood pressure, and cardiovascular outcomes – Authors' reply. <i>Lancet, The</i> , 2013, 381, 1982-1983.	6.3	0
124	Exploring Issues in Difficult-to-Treat Hypertension. <i>Journal of Clinical Hypertension</i> , 2013, 15, 859-864.	1.0	2
125	The Human Side of Failed Hypertension Treatment. <i>Journal of Clinical Hypertension</i> , 2013, 15, 762-764.	1.0	1
126	Progression of Chronic Kidney Disease in Patients with Diabetes: Implications for Practice. <i>Endocrine Practice</i> , 2013, 19, 8-13.	1.1	0



#	ARTICLE	IF	CITATIONS
127	The Physician Payments Sunshine Act: A Setback for Medical Progress. <i>Drug Information Journal</i> , 2012, 46, 292-293.	0.5	1
128	Renal outcomes in hypertensive Black patients at high cardiovascular risk. <i>Kidney International</i> , 2012, 81, 568-576.	2.6	31
129	Azilsartan Medoxomil Plus Chlorthalidone Reduces Blood Pressure More Effectively Than Olmesartan Plus Hydrochlorothiazide in Stage 2 Systolic Hypertension. <i>Hypertension</i> , 2012, 60, 310-318.	1.3	59
130	Cardiovascular outcomes in hypertensive patients. <i>Journal of Hypertension</i> , 2012, 30, 2213-2222.	0.3	25
131	Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study. <i>Blood Pressure</i> , 2012, 21, 82-87.	0.7	4
132	Safety and Efficacy of Low Blood Pressures Among Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2012, 59, 74-83.	1.2	164
133	Antihypertensive Efficacy of Hydrochlorothiazide vs Chlorthalidone Combined with Azilsartan Medoxomil. <i>American Journal of Medicine</i> , 2012, 125, 1229.e1-1229.e10.	0.6	71
134	Association of Clinical Researchers and Educators A Statement on Relationships Between Physicians and Industry. <i>Endocrine Practice</i> , 2012, 18, 1029-1037.	1.1	3
135	Blood Pressure—Lowering Efficacy of the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone: A Factorial Study. <i>Journal of Clinical Hypertension</i> , 2012, 14, 284-292.	1.0	41
136	Blood Pressure Effects of Combined $\beta$ -Blocker and Angiotensin-Converting Enzyme Inhibitor Therapy Compared With the Individual Agents: A Placebo-Controlled Study With Nebivolol and Lisinopril. <i>Journal of Clinical Hypertension</i> , 2012, 14, 588-592.	1.0	23
137	Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension. <i>Hypertension</i> , 2011, 57, 413-420.	1.3	192
138	ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2037-2114.	1.2	419
139	ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. <i>Journal of the American Society of Hypertension</i> , 2011, 5, 259-352.	2.3	125
140	The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure. <i>Journal of Clinical Hypertension</i> , 2011, 13, 81-88.	1.0	127
141	ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. <i>Circulation</i> , 2011, 123, 2434-2506.	1.6	381
142	Efficacy and Duration of Benazepril Plus Amlodipine or Hydrochlorothiazide on 24-Hour Ambulatory Systolic Blood Pressure Control. <i>Hypertension</i> , 2011, 57, 174-179.	1.3	55
143	Telmisartan in High-Risk Cardiovascular Patients. <i>American Journal of Cardiology</i> , 2010, 105, 36A-43A.	0.7	3
144	Effect of Combining Extended-Release Carvedilol and Lisinopril in Hypertension: Results of the COSMOS Study. <i>Journal of Clinical Hypertension</i> , 2010, 12, 678-686.	1.0	23

#	ARTICLE	IF	CITATIONS
145	Divergent Results Using Clinic and Ambulatory Blood Pressures. <i>Hypertension</i> , 2010, 56, 824-830.	1.3	169
146	Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2010, 56, 77-85.	1.2	215
147	Combination therapy in hypertension. <i>Journal of the American Society of Hypertension</i> , 2010, 4, 90-98.	2.3	156
148	Treatment of Patients with Hypertension and Arthritis Pain: New Concepts. <i>American Journal of Medicine</i> , 2009, 122, S16-S22.	0.6	12
149	A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2009, 374, 1423-1431.	6.3	277
150	Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?. <i>Journal of Hypertension</i> , 2009, 27, S9-S14.	0.3	9
151	Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. <i>Journal of Hypertension</i> , 2009, 27, 1360-1369.	0.3	311
152	The Diabetes Subgroup Baseline Characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) Trial. <i>Journal of the Cardiometabolic Syndrome</i> , 2008, 3, 229-233.	1.7	9
153	β <sub>2</sub> -Blockers in the Treatment of Hypertension: New Data, New Directions. <i>Journal of Clinical Hypertension</i> , 2008, 10, 234-238.	1.0	7
154	ONTARGET: Questions Asked, Questions Answered. <i>Journal of Clinical Hypertension</i> , 2008, 10, 427-430.	1.0	0
155	Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. <i>New England Journal of Medicine</i> , 2008, 359, 2417-2428.	13.9	1,849
156	Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: The ACCOMPLISH Study. <i>Blood Pressure</i> , 2008, 17, 7-17.	0.7	49
157	Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective. <i>Blood Pressure</i> , 2008, 17, 260-269.	0.7	10
158	Exceptional early blood pressure control rates: The ACCOMPLISH trial. <i>Blood Pressure</i> , 2007, 16, 80-86.	0.7	114
159	Efficacy and Safety of Darusentan in Patients With Resistant Hypertension: Results From a Randomized, Double-blind, Placebo-controlled Dose-ranging Study. <i>Journal of Clinical Hypertension</i> , 2007, 9, 760-769.	1.0	88
160	Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk. <i>Blood Pressure</i> , 2007, 16, 13-19.	0.7	65
161	New Opportunities in Cardiovascular Patient Management: A Survey of Clinical Data on the Combination of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. <i>American Journal of Cardiology</i> , 2007, 100, S45-S52.	0.7	12
162	Secondary analysis of the VALUE trial: Intriguing new questions. <i>Current Hypertension Reports</i> , 2007, 9, 261-263.	1.5	0

#	ARTICLE	IF	CITATIONS
163	The Metabolic Syndrome. , 2007, , 678-690.		0
164	Expanding the opportunities for blocking the renin-angiotensin system: introduction to a special supplement. Reviews in Cardiovascular Medicine, 2007, 8 Suppl 2, S1-6.	0.5	2
165	Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. American Heart Journal, 2006, 151, 176-184.	1.2	58
166	An Effectiveness Study Comparing Algorithm-Based Antihypertensive Therapy With Previous Treatments Using Conventional and Ambulatory Blood Pressure Measurements. Journal of Clinical Hypertension, 2006, 8, 241-252.	1.0	3
167	Expanding the Scope of Hypertension: Are We Creating New Diseases?. Journal of Clinical Hypertension, 2006, 8, 615-618.	1.0	1
168	Efficacy of a Once-Daily Formulation of Carvedilol for the Treatment of Hypertension. Journal of Clinical Hypertension, 2006, 8, 840-849.	1.0	31
169	Hypertension treatment and implications of recent cardiovascular outcome trials. Journal of Hypertension, 2006, 24, S37-S44.	0.3	11
170	Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. Journal of Hypertension, 2006, 24, 2163-2168.	0.3	138
171	Controlled-Release Carvedilol in the Treatment of Essential Hypertension. American Journal of Cardiology, 2006, 98, 32-38.	0.7	30
172	The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial. Hypertension, 2006, 48, 385-391.	1.3	138
173	Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?. Reviews in Cardiovascular Medicine, 2006, 7, 45-54.	0.5	35
174	Managing the patient at risk for a second stroke. Journal of Hypertension, 2005, 23, S41-S47.	0.3	7
175	Clinical Trials Report. Current Hypertension Reports, 2005, 7, 235-237.	1.5	0
176	Is There More to Life Than Blood Pressure?. Journal of Clinical Hypertension, 2005, 7, 149-151.	1.0	1
177	The Role of the New $\beta$ -Blockers in Treating Cardiovascular Disease. American Journal of Hypertension, 2005, 18, 169-176.	1.0	101
178	Angiotensin-II receptor blockers for hypertension and heart failure: quality of life and outcomes. Managed Care Interface, 2005, 18, 47-54.	0.2	6
179	Treatment of Elderly Hypertensive Patients With a Delayed-Release Verapamil Formulation in a Community-Based Trial. The American Journal of Geriatric Cardiology, 2004, 13, 131-136.	0.7	5
180	Angiotensin II Receptor Blockers in Older Patients. The American Journal of Geriatric Cardiology, 2004, 13, 197-205.	0.7	7

#	ARTICLE	IF	CITATIONS
181	Clinical Trials Report. Current Hypertension Reports, 2004, 6, 291-292.	1.5	3
182	Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. American Journal of Hypertension, 2004, 17, 37-42.	1.0	54
183	Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. American Journal of Hypertension, 2004, 17, 252-259.	1.0	133
184	Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. American Journal of Hypertension, 2004, 17, 793-801.	1.0	97
185	Hypertension, the Metabolic Syndrome, and the Risk of Developing Diabetes: Is It Time to Change the Guidelines?. Journal of Clinical Hypertension, 2004, 6, 425-427.	1.0	12
186	Use of an Olmesartan Medoxomil-Based Treatment Algorithm for Hypertension Control. Journal of Clinical Hypertension, 2004, 6, 168-399.	1.0	42
187	Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, The, 2004, 363, 2022-2031.	6.3	2,422
188	Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet, The, 2004, 363, 2049-2051.	6.3	540
189	Circadian variations in cardiovascular disease: chronotherapeutic approaches to the management of hypertension. Reviews in Cardiovascular Medicine, 2004, 5, 148-55.	0.5	9
190	Clinical Trials Report. Current Hypertension Reports, 2003, 5, 319-321.	1.5	0
191	The ALLHAT Report: A Case of Information and Misinformation. Journal of Clinical Hypertension, 2003, 5, 9-13.	1.0	49
192	The JNC 7 Report: Challenges and Dilemmas in Writing Guidelines. Journal of Clinical Hypertension, 2003, 5, 282-286.	1.0	0
193	Quality of Life Measured in a Practice-Based Hypertension Trial of an Angiotensin Receptor Blocker. Journal of Clinical Hypertension, 2003, 5, 325-329.	1.0	13
194	Creating a Combination Antihypertensive Regimen: What Does the Research Show?. Journal of Clinical Hypertension, 2003, 5, 12-20.	1.0	20
195	Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. American Journal of Hypertension, 2003, 16, 460-466.	1.0	18
196	Review: Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2003, 4, 62-73.	1.0	9
197	A Spectrum of Clinical Issues in Geriatric Cardiology. The American Journal of Geriatric Cardiology, 2003, 12, 81-82.	0.7	0
198	Outcomes of Treating Hypertension in the Elderly: A Short Commentary on Current Issues. The American Journal of Geriatric Cardiology, 2003, 12, 14-18.	0.7	8

#	ARTICLE	IF	CITATIONS
199	Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial. JAMA - Journal of the American Medical Association, 2003, 289, 2073.	3.8	646
200	Evaluation of the 24-hour effects of the angiotensin II receptor blockers: means to improve cardiovascular outcomes?. Blood Pressure Monitoring, 2003, 8, 215-222.	0.4	1
201	The telmisartan Programme of Research to show Telmisartan End-organ protection (PROTECTION) Programme. Journal of Hypertension, 2003, 21, S37-S46.	0.3	36
202	Hypertension at Elderly Age: What We Know and What We Must Learn. The American Journal of Geriatric Cardiology, 2002, 11, 8-10.	0.7	1
203	Calcium Channel Antagonists in the Treatment of Hypertension. American Journal of Cardiovascular Drugs, 2002, 2, 415-431.	1.0	18
204	Clinical implications of aldosterone blockade. American Heart Journal, 2002, 144, S12-S18.	1.2	28
205	The 24-hour blood pressure pattern: does it have implications for morbidity and mortality?. American Journal of Cardiology, 2002, 89, 27-33.	0.7	51
206	Contrasting clinical properties and exercise responses in obese and lean hypertensive patients. Journal of the American College of Cardiology, 2001, 37, 169-174.	1.2	107
207	Arterial compliance abnormalities in isolated systolic hypertension. American Journal of Hypertension, 2001, 14, 1007-1011.	1.0	64
208	The effect of antihypertensive drugs on vascular compliance. Current Hypertension Reports, 2001, 3, 297-304.	1.5	33
209	One-Year Study of Felodipine or Placebo for Stage 1 Isolated Systolic Hypertension. Hypertension, 2001, 38, 1118-1123.	1.3	26
210	Differing Roles of Body Mass and the Renin-Angiotensin System in Mediating the Hypertension Syndrome. American Journal of Nephrology, 2000, 20, 169-174.	1.4	10
211	Rationale and Design for the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. Contemporary Clinical Trials, 1998, 19, 370-390.	2.0	88
212	Editorial. American Journal of Hypertension, 1998, 11, 1495-1496.	1.0	4
213	Hemodynamic Patterns of Age-Related Changes in Blood Pressure. Circulation, 1997, 96, 308-315.	1.6	1,795
214	THE THERAPEUTIC IMPLICATIONS OF LEFT VENTRICULAR HYPERTROPHY IN THE HYPERTENSIVE PATIENT. American Journal of Therapeutics, 1995, 2, 972-977.	0.5	2
215	Extended-release felodipine in patients with mild to moderate hypertension. Clinical Pharmacology and Therapeutics, 1994, 55, 346-352.	2.3	11
216	Lead-Induced Hypertension: Possible Role of Endothelial Factors. American Journal of Hypertension, 1993, 6, 723-729.	1.0	110

#	ARTICLE	IF	CITATIONS
217	Clinical Experience With the Angiotensin II Receptor Antagonist Losartan. American Journal of Hypertension, 1992, 5, 247S-251S.	1.0	85
218	Heredity and hypertension: Impact on metabolic characteristics. American Heart Journal, 1992, 124, 435-440.	1.2	46
219	Does the Concept of a Hypertension Syndrome Apply in the Aging?. The American Journal of Geriatric Cardiology, 1992, 1, 10-12.	0.7	0
220	Overview of Fosinopril. Drug Investigation, 1991, 3, 3-11.	0.6	14
221	Sympathetic Nervous System and Hypertension. American Journal of Hypertension, 1989, 2, 147S-152S.	1.0	7
222	Blood Pressure Mechanisms and the Sympathetic Nervous System. American Journal of Hypertension, 1989, 2, 101S-102S.	1.0	0
223	Clinical Pharmacology of Centrally Acting Antihypertensive Agents. Journal of Clinical Pharmacology, 1989, 29, 598-602.	1.0	6
224	Characterization of Antihypertensive Therapy by Whole-Day Blood Pressure Monitoring. JAMA - Journal of the American Medical Association, 1988, 259, 3281.	3.8	78
225	Blood Pressure Monitoring for Assessing the Duration of Action of Antihypertensive Treatment. Journal of Clinical Pharmacology, 1987, 27, 751-755.	1.0	15
226	Effect of the calcium channel blocker nitrendipine on left ventricular mass in patients with hypertension. Clinical Pharmacology and Therapeutics, 1986, 40, 679-685.	2.3	31
227	The circadian blood pressure pattern in ambulatory normal subjects. American Journal of Cardiology, 1984, 54, 115-119.	0.7	128
228	The Combined Alpha and Beta Adrenergic Blocker Labetalol and Propranolol in the Treatment of High Blood Pressure: Similarities and Differences. Journal of Clinical Pharmacology, 1984, 24, 103-112.	1.0	16
229	Cardiac muscle mass during vasodilation therapy of hypertension. Clinical Pharmacology and Therapeutics, 1983, 33, 727-732.	2.3	74
230	Vasoconstrictor Effects of Aldosterone in Isolated Vascular Tissue. Clinical and Experimental Hypertension, 1982, 4, 1583-1591.	0.3	14
231	Renin Subgroups in Essential Hypertension. Clinical and Experimental Hypertension, 1982, 4, 1817-1834.	0.3	18
232	The Role of Aldosterone in the Response to Treatment of Primary Hypertension. Clinical and Experimental Hypertension, 1982, 4, 1923-1934.	0.3	0
233	Mineralocorticoids in Essential and Secondary Hypertension Introduction to the Symposium. Clinical and Experimental Hypertension, 1982, 4, 1447-1450.	0.3	0
234	Differential Effects of Diuresis and Beta Adrenoreceptor Blockade During Angiotensin Converting Enzyme Inhibition in Patients with Severe Hypertension. Journal of Clinical Pharmacology, 1982, 22, 179-186.	1.0	11

#	ARTICLE	IF	CITATIONS
235	Changes in ventricular septal thickness during diuretic therapy. <i>Clinical Pharmacology and Therapeutics</i> , 1982, 32, 283-288.	2.3	96
236	A vasodilator that avoids renin stimulation and fluid retention: Antihypertensive treatment with trimazosin. <i>Clinical Pharmacology and Therapeutics</i> , 1982, 31, 572-578.	2.3	14
237	Centrally Acting Antihypertensive Agents: A Comparison of Lofexidine with Clonidine. <i>Journal of Clinical Pharmacology</i> , 1981, 21, 65-71.	1.0	10
238	Low-dose diuretic and beta adrenoceptor blocker in essential hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 28, 149-158.	2.3	15
239	The Abrupt Discontinuation of Antihypertensive Treatment. <i>Journal of Clinical Pharmacology</i> , 1979, 19, 476-486.	1.0	37
240	The possible importance of aldosterone as well as renin in the long-term antihypertensive action of propranolol. <i>American Journal of Medicine</i> , 1978, 64, 187-192.	0.6	35
241	Disparate Patterns of Aldosterone Response During Diuretic Treatment of Hypertension. <i>Annals of Internal Medicine</i> , 1977, 87, 558.	2.0	58